Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources.
American College of Radiology, Reston, VA, USA. research@astro.org
Gary L
GL
Dillehay
Nancy A
NA
Ellerbroek
Helena
H
Balon
David R
DR
Brill
Perry W
PW
Grigsby
Roger M
RM
Macklis
Peter M
PM
Mauch
Tariq A
TA
Mian
Louis
L
Potters
Edward B
EB
Silberstein
Timothy R
TR
Williams
Jeffrey C Y
JC
Wong
Laurie E
LE
Gaspar
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001201:Ascites / Q000532:radiotherapy; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary; D017608:Chromium Compounds / Q000627:therapeutic use; D006801:Humans; D006980:Hyperthyroidism / Q000532:radiotherapy; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000532:radiotherapy; D009942:Organometallic Compounds / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D010146:Pain / Q000209:etiology / Q000532:radiotherapy; D010356:Patient Isolation / Q000592:standards; D010710:Phosphates / Q000627:therapeutic use; D016066:Pleural Effusion, Malignant / Q000532:radiotherapy; D011087:Polycythemia Vera / Q000532:radiotherapy; D011835:Radiation Protection / Q000592:standards; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use*; D012974:Sodium Iodide / Q000627:therapeutic use; D013326:Strontium Radioisotopes / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000532:radiotherapy; D013964:Thyroid Neoplasms / Q000532:radiotherapy; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D017608:Chromium Compounds; D007457:Iodine Radioisotopes; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D010710:Phosphates; D019275:Radiopharmaceuticals; D013326:Strontium Radioisotopes; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan; C061972:samarium Sm-153 lexidronam; C509369:chromic phosphate; D012974:Sodium Iodide; C119496:tositumomab I-131; C018279:sodium phosphate